Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

66
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
66
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

73
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
73
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

121
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
121
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

131
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
131
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

64
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
64
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

58
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
58

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effective parallel evaluation of molecular design, expression and bioactivity of novel recombinant butyrylcholinesterase medical countermeasures.

Chemico-biological interactions·2024
Same author

Design and optimization of membrane chromatography for monoclonal antibody charge variant separation.

Biotechnology progress·2022
Same author

Strategies for developing a recombinant butyrylcholinesterase medical countermeasure for Organophosphorus poisoning.

Chemico-biological interactions·2022
Same author

Protein Expression Optimization Strategies in E. coli: A Tailored Approach in Strain Selection and Parallelizing Expression Conditions.

Methods in molecular biology (Clifton, N.J.)·2022
Same author

Yeast-based bioproduction of disulfide-rich peptides and their cyclization via asparaginyl endopeptidases.

Nature protocols·2021
Same author

Intensified Downstream Processing of Monoclonal Antibodies Using Membrane Technology.

Biotechnology journal·2020

Related Experiment Video

Updated: Mar 5, 2026

Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

9.8K

Platform technologies for modern vaccine manufacturing.

Hayley K Charlton Hume1, Linda H L Lua1

  • 1The University of Queensland, Protein Expression Facility, St Lucia, QLD 4072, Australia.

Vaccine
|March 29, 2017
PubMed
Summary

Modern vaccine design leverages computational tools for better antigen understanding. Promising modular vaccine platforms, like virus-like particles and liposomes, offer rapid, low-cost, and safe vaccine development.

Keywords:
LiposomeModularPlatform technologyVaccine designVirus-like particle

More Related Videos

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.9K
Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

5.7K

Related Experiment Videos

Last Updated: Mar 5, 2026

Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

9.8K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.9K
Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

5.7K

Area of Science:

  • Immunology and vaccinology
  • Computational biology
  • Biotechnology

Background:

  • Understanding of antigenic components and immune interactions is crucial for advanced vaccine design.
  • Modular vaccine platforms enhance immunogenicity by strategically presenting peptide and protein antigens.
  • Traditional vaccine manufacturing faces challenges that novel platforms aim to address.

Purpose of the Study:

  • To review advanced vaccine design strategies.
  • To introduce and discuss two promising modular vaccine platforms: virus-like particles and liposomes.
  • To explore the methodologies and challenges associated with these platforms.

Main Methods:

  • Review of scientific literature on vaccine platforms.
  • Analysis of computational tools in antigen-immune system interaction studies.
  • Comparative discussion of virus-like particle and liposome platform technologies.

Main Results:

  • Modular vaccine platforms enable enhanced immunogenicity and overcome traditional manufacturing limitations.
  • Virus-like particle and liposome platforms show significant potential for vaccine development.
  • Computational tools facilitate a sophisticated approach to vaccine design.

Conclusions:

  • Modular vaccine platforms represent a significant advancement in vaccine development.
  • Virus-like particle and liposome platforms offer a viable path for rapid, cost-effective, and safe vaccine production.
  • Further research into methodologies and challenges is essential for optimizing these platforms.